Press Releases

Year

Nov 24, 2020

Vaxcyte to Present at Evercore ISI 3rd Annual HealthCONx Conference

FOSTER CITY, Calif. , Nov. 24, 2020 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. , formerly known as SutroVax, a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases

Additional Formats

PDF Version

Nov 12, 2020

Vaxcyte Reports Third Quarter 2020 Financial Results and Provides Business Update

FOSTER CITY, Calif. , Nov. 12, 2020 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. , formerly known as SutroVax , a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases

Additional Formats

PDF Version

Nov 10, 2020

Vaxcyte to Present at Jefferies Virtual London Healthcare Conference

FOSTER CITY, Calif. , Nov. 10, 2020 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. , formerly known as SutroVax , a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases

Additional Formats

PDF Version

Sep 09, 2020

Vaxcyte to Present at 2020 Cantor Virtual Global Healthcare Conference

FOSTER CITY, Calif. , Sept. 09, 2020 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. , formerly known as SutroVax , a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases

Additional Formats

PDF Version

Aug 12, 2020

Vaxcyte Reports Second Quarter 2020 Financial Results and Provides Business Update

Jun 16, 2020

Vaxcyte Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

FOSTER CITY, Calif. , June 16, 2020 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today

Additional Formats

PDF Version

Jun 11, 2020

Vaxcyte Announces Pricing of Upsized Initial Public Offering

Foster City, CA, June 11, 2020 (GLOBE NEWSWIRE) -- Vaxcyte, Inc., a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced the

Additional Formats

PDF Version

Jun 03, 2020

Vaxcyte Appoints Halley E. Gilbert to Board of Directors

Foster City, CA, June 3, 2020 – Vaxcyte, Inc ., formerly known as SutroVax, a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced the

Additional Formats

PDF Version

May 21, 2020

SutroVax Announces Name Change to Vaxcyte

Foster City, CA, May 21, 2020 – SutroVax , Inc., a next-generation vaccine company, today announced that it has changed its name to Vaxcyte, Inc. The new name more accurately reflects the Company’s mission to improve global health by developing superior and novel vaccines designed to prevent or

Additional Formats

PDF Version

May 04, 2020

SutroVax Appoints Andrew Guggenhime as Chief Financial Officer and Chief Business Officer

Foster City, CA, May 4, 2020 – SutroVax , a biopharmaceutical company dedicated to the development of superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced the appointment of Andrew Guggenhime as Chief Financial

Additional Formats

PDF Version

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 12